GH1 and cardiovascular disorder: Considering our observation of greater interday glycemic variability with once-weekly GH treatment than with once-daily GH treatment, CGM-based monitoring may be crucial, particularly in individuals with diabetes or those with a high risk of cardiovascular disease.